A
Antoine G. van der Heijden
Researcher at Radboud University Nijmegen
Publications - 79
Citations - 5359
Antoine G. van der Heijden is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Bladder cancer & Medicine. The author has an hindex of 23, co-authored 58 publications receiving 3567 citations. Previous affiliations of Antoine G. van der Heijden include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
J. Alfred Witjes,Thierry Lebret,Eva Comperat,Nigel C. Cowan,Maria De Santis,Harman Maxim Bruins,Virginia Hernández,Estefania Linares Espinós,James Dunn,Mathieu Rouanne,Yann Neuzillet,Erik Veskimäe,Antoine G. van der Heijden,Georgios Gakis,Maria J. Ribal +14 more
TL;DR: The current summary of the EAU Muscle- invasive and Metastatic Bladder Cancer Guidelines provides an up-to-date overview of the available literature and evidence dealing with diagnosis, treatment, and follow-up of patients with metastatic and muscle-invasive bladder cancer.
Journal ArticleDOI
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
J. Alfred Witjes,Eva Comperat,Nigel C. Cowan,Maria De Santis,Georgios Gakis,Thierry Lebret,Maria J. Ribal,Antoine G. van der Heijden,Amir Sherif +8 more
TL;DR: It is recommended that chemotherapy be administered before radical treatment and that bladder removal be the standard of care for disease confined to the bladder for patients with muscle-invasive or metastatic BCa.
Journal ArticleDOI
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes,H.M. Bruins,Richard Cathomas,Eva Compérat,Nigel C. Cowan,Georgios Gakis,Virginia Hernández,Estefania Linares Espinós,Anja Lorch,Yann Neuzillet,Mathieu Rouanne,George N. Thalmann,Erik Veskimäe,Maria J. Ribal,Antoine G. van der Heijden +14 more
TL;DR: The results of a collaborative multistakeholder consensus project on advanced bladder cancer (BC) have been incorporated in the 2020 guidelines, addressing those areas where it is unlikely that prospective comparative studies will be conducted.
Journal ArticleDOI
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Tom J.H. Arends,Ofer Nativ,Massimo Maffezzini,Ottavio De Cobelli,Giorgio Canepa,F. Verweij,Boaz Moskovitz,Antoine G. van der Heijden,J. Alfred Witjes +8 more
TL;DR: CHT is an option for BCG therapy as adjuvant treatment for intermediate- and high-risk papillary NMIBC and appears to be safe and has higher 24-mo recurrence-free survival thanBCG therapy.
Journal ArticleDOI
The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review
Harman Maxim Bruins,Erik Veskimäe,Virginia Hernández,Mari Imamura,Molly M. Neuberger,Philipp Dahm,Philipp Dahm,Fiona Stewart,Thomas B. Lam,James N'Dow,Antoine G. van der Heijden,Eva Comperat,Nigel C. Cowan,Maria De Santis,Georgios Gakis,Thierry Lebret,Maria J. Ribal,Amir Sherif,J. Alfred Witjes +18 more
TL;DR: The current literature suggests that removal of lymph nodes in bladder cancer surgery is beneficial and might result in better outcomes in terms of prolonging survival; however, the quality of the available studies is poor, and high-quality studies are needed.